← Leaderboards
Tsuyoshi Uehara
Venatorx Pharmaceuticals, Inc.
$2,000,000
Attributed
$2,000,000
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1M · FY2024–25$1M$750K$500K$250K$0
'24
'25
Funding mix
By agency
NIH$2,000,000 · 1
By mechanism
R44$2,000,000 · 1
Top collaborators
No co-investigators on record.
Most similar at Venatorx Pharmaceuticals, Inc.
Same institution · by research overlap
- Luigi Xerri$39,662,982
- Steven Armen Boyd$13,685,544
- Denis Marc Daigle$7,512,530
- Bin Liu$3,147,000
Others in their field
Other Rising Stars on “Acinetobacter Baumannii”
- Justin Blaine Schaal · University Of Southern California$3,025,760
- Paul Sebahar · Curza Inc$2,858,436
- Yanan Zhao · State University Of New York At Buffalo$1,596,741
- Despoina Mavridou · University Of Texas At Austin$1,558,092
- Vidmantas Petraitis · Hackensack University Medical Center$1,428,749
- Yinzhi Lang · University Of Florida$1,261,878
Research focus
Acinetobacter BaumanniiAffinityAnimalsAnti-Bacterial AgentsAntibioticsApplications GrantsBactericideBeta-LactamaseBeta-Lactam ResistanceBeta-LactamsBiologicalCarbapenemaseCarbapenem ResistanceCarbapenem-Resistant AcinetobacterCarbapenemsCell WallCenters For Disease Control And Prevention (U.S.)CephalosporinsChemistryClassificationCollectionComplexDesignAcinetobacter